Kuros Biosciences AG

Kuros Biosciences Expands into Extremities Markets

Kuros reports 149% increase in direct MagnetOs sales and exceeds cash flow breakeven in the first nine months of 2024

Kuros Biosciences Reports First Half of 2024 Results

Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft

Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023

Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand

Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA

Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA

Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages

Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management

Kuros Biosciences Reports Results for First Half 2023

Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023

Kuros Biosciences reports results for the full year 2022

Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft

Kuros Biosciences Announces Changes to Executive Management Team

Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH

Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules

Kuros reports 73% increase in MagnetOs sales in first nine months of 2022

Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week

Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting

Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting

Kuros Biosciences Appoints Chris Fair as Chief Operating Officer

Kuros Biosciences announces successful CHF 6.0 million private placement

Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones